British Land REIT: Life Science REIT Deal Explained

Quick answer for British Land REIT investors

British Land's shareholder FAQ describes the Life Science REIT acquisition as completed, with total consideration of £146 million made up of £49 million in cash and £97 million in new British Land shares.

In the recommended offer announcement, British Land said the original terms were 14.1p in cash plus 0.07 new British Land shares for each Life Science REIT share.

Using British Land's 410.0p closing price on 27 January 2026, the announcement said the package valued each Life Science REIT share at about 42.8p and Life Science REIT's issued and to-be-issued share capital at about £150 million.

That is the useful frame from the recommended offer announcement for British Land REIT investors: this was not just a headline property purchase, it was a cash-and-share acquisition designed to add more Science & Technology exposure.

This article does not provide a live BR Land share price. Instead, it explains the acquisition terms and why they mattered for British Land and Life Science REIT shareholders.

The terms that matter

The original offer represented about a 21% premium to Life Science REIT's 35.4p closing share price on 27 January 2026 and about a 15% premium to its three-month VWAP of 37.3p, according to the offer announcement.

The original offer was also about a 26% discount to Life Science REIT's unaudited EPRA NTA of 57.7p per share as at 31 December 2025, according to the same offer announcement.

The offer valuation shows the trade off for Life Science REIT investors: a premium to the market price, but an exit below the reported net tangible asset value.

That is why this deal was not an obvious win at any price. It was a pragmatic route out of a small listed REIT at a premium to the share price, while still leaving British Land with the chance to capture any future leasing and rental upside.

Strategic logic - British Land doubles down on Science & Technology

British Land framed the deal as an expansion of its Science & Technology campus strategy in London, Oxford and Cambridge.

The Life Science REIT portfolio comprised five UK Golden Triangle assets, including London Knowledge Quarter assets, Oxford Technology Park and Cambridge assets.

British Land said it expected cost synergies, immediate EPS accretion, EPRA NTA neutrality and upside from leasing vacant space and capturing reversion in the recommended offer announcement.

As of 31 December 2025, the Life Science REIT portfolio was valued at about £332.6 million, with a contracted rent roll of £18.74 million and an estimated rental value of £26.5 million, according to the offer announcement.

British Land's post-completion FAQ says the acquired assets are expected to generate £18 million of FY27 net rental income, rising to a stabilised annual £25 million.

My read: the acquisition makes most sense if British Land can lease the vacant space well and keep broadening demand beyond pure life sciences into the wider innovation market.

What changed since the original announcement?

Life Science REIT shareholders approved the scheme on 19 March 2026, according to the shareholder approval announcement.

At the Court Meeting, 99.25% of scheme shares voted were in favour, according to the same announcement.

At the General Meeting, 99.28% of voted shares supported the resolution, according to the same announcement.

British Land's FAQ then records the completed acquisition and the final mix of cash and shares.

That means the old "what to watch next" question has moved on from whether shareholders approve the deal to how British Land performs with the assets.

What this means if you owned Life Science REIT shares

The Life Science REIT board backed the offer even though it was below EPRA NTA, with the offer announcement saying recent indicative asset bids were unattractive.

The upside was a mix of cash and British Land shares; the downside was giving up any asset-level recovery that might have come from leasing and reversion.

For Life Science REIT holders, my view is unchanged from the original piece: the deal looked pragmatic rather than exciting.

What this means if you own British Land shares

For British Land, this was a focused bolt-on for a Science & Technology strategy it had already chosen.

The risk is execution: leasing, integration and whether the expected cost savings and rental upside actually arrive.

I would watch leasing progress at Oxford Technology Park, rent capture versus ERV and whether the acquired assets deliver the income British Land flagged after completion.

For a separate UK deal situation, see my note on Science in Sport PLC Reports Turnaround Progress and Recommended Acquisition by bd Capital.

Jargon buster

• Scheme of arrangement: a court-approved process to acquire a company with set voting thresholds.
• EPRA NTA: an industry measure of net asset value that focuses on long term tangible assets.
• ERV: estimated rental value - the market rent the space could achieve when fully let.
• Reversion: uplift in rent as contracted rents move towards ERV over time.
• WAULT: weighted average unexpired lease term - a measure of income duration.